Sanjivani Paranteral Ltd.

Healthcare · Pharmaceuticals & Biotechnology

BSE: 531569
₹167.00
Sept. 30, 2026 · BSE · bse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #116 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

CompanyMarket cap (₹ Cr)PE (TTM)ROE1Y returnDiv. yieldQualityValuationMomentum
Sun Pharmaceutical Industries Limited 435,863 146.5 13.7% 11.0% — 72 8 30
Divi's Laboratories Limited 246,660 83.9 15.3% 62.7% 0.32% 70 4 51
Torrent Pharmaceuticals Limited 162,454 78.2 12.2% 34.6% 0.79% 56 0 31
Zydus Lifesciences Limited 115,910 33.3 17.3% 17.2% 0.09% 74 24 84
Cipla Limited 108,736 35.4 11.2% -11.0% 0.97% 73 29 62
Laurus Labs Limited 106,969 122.5 17.1% 127.1% — 78 24 53
Mankind Pharma Limited 103,406 47.4 11.7% 2.6% — 68 12 86
Dr. Reddy's Laboratories Limited 102,916 154.7 10.9% -0.9% — 62 33 71
Sanjivani Paranteral Ltd. (this stock) 205 27.2 16.9% -56.2% — 76 35 29

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value
₹213 Cr
EV / EBITDA
18.5x
EV / Sales
3.21x
Market cap / Sales
3.09x
Earnings yield
3.67%

Quarterly Financials

↑ Positive
Quarterly Revenue

Jun 2026 quarterly revenue is Rs 20 Cr, up 9.4% YoY.

Period endRevenue (₹ Cr)PBT (₹ Cr)Net profit (₹ Cr)Basic EPS
June 30, 2026 19 3 — ₹1.8700
March 31, 2026 11 1 — ₹0.8000
Dec. 31, 2025 21 3 3 ₹2.1300
Sept. 30, 2025 15 2 2 ₹1.3300
June 30, 2025 18 2 2 ₹1.4600
March 31, 2025 18 3 2 ₹1.8400
Dec. 31, 2024 17 3 2 ₹1.6200
Sept. 30, 2024 18 3 2 ₹1.9600
June 30, 2024 16 2 2 ₹1.4700
March 31, 2024 13 2 1 ₹1.0800
Dec. 31, 2023 15 2 2 ₹1.6500
Sept. 30, 2023 14 2 2 ₹1.7060
June 30, 2023 13 2 2 ₹1.5500

Quarterly income statement (standalone, ₹ Cr)

IndicatorJun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23
Total income (before exceptional items)20112116181918191713151413
Operating revenue19112115181817181613151413
Other income0100000000000
Operating expenses16101713151615151411131211
Operating profit3142333322222
Operating profit margin17.5%8.7%17.2%14.5%14.8%14.4%14.7%15.7%14.2%16.8%13.1%15.1%16.0%
Depreciation0000000000000
Interest0000000000000
Exceptional items, gain / (loss)—————————————
Profit before tax3132233322222
Tax1011101111000
Net profit——32222221222
EPS1.870.802.131.331.461.841.621.961.471.081.651.711.55
Net profit (TTM)——87887766654
EPS (TTM)6.135.726.766.256.886.896.136.165.915.995.915.214.26

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

IndicatorCAGR 3YCAGR 5YMar 26Mar 25Mar 24Mar 23Mar 22Mar 21Mar 20Mar 19Mar 18Mar 17
Total income (before exceptional items) 22.3% 21.1% 66†71†55†36†31†25†17†26†18†—
Operating revenue 22.2% 20.9% 65†70†54†35†31†25†16†25†18†36†
Other income — — 1†1†1†1†0†0†0†1†0†—
Operating expenses — — 55†60†46†30†25†23†17†——42†
Operating profit 18.6% 34.4% 9†10†8†6†6†2†-0†——-7†
Operating profit margin — — 14.5%†14.8%†15.1%†15.9%†18.7%†8.5%†-2.0%†——-19.1%†
Depreciation — — 1†1†1†1†1†1†1†——1†
Interest — — 1†1†0†0†0†0†1†0†0†5†
Exceptional items, gain / (loss) — — 0†0†0†0†0†0†0†0†0†0†
Profit before tax 23.1% 45.6% 9†10†8†5†5†1†-2†-2†-53†-17†
Tax — — 2†2†1†—————-0†—
Net profit — — —8†6†5†5†1†-2†-2†-53†-17†
EPS 8.2% 27.8% 5.72†6.89†5.99†4.51†4.96†1.68†-2.90†———

† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

RatioMar 26Mar 25Mar 24Mar 23Mar 22Mar 21Mar 20Mar 19Mar 18Mar 17
Operating margin14.5%†14.8%†15.1%†15.9%†18.7%†8.5%†-2.0%†——-19.1%†
EBIT margin15.1%†15.6%†14.4%†14.9%†16.6%†6.1%†-7.0%†-7.8%†-294.7%†-35.7%†
PBT margin14.3%†14.8%†13.9%†13.9%†15.9%†5.6%†-11.1%†-9.2%†-297.2%†-49.2%†
Net margin—11.6%†11.3%†12.7%†15.8%†5.7%†-10.4%†-8.2%†-295.4%†-48.6%†
Interest coverage18.12x†18.48x†30.87x†14.78x†23.88x†12.22x†-1.76x†-6.00x†-118.94x†-2.64x†
Dividend payout——————————
Earnings retention——————————
Current ratio2.24x1.86x————————
Quick ratio1.80x1.35x————————
Debt to equity0.19x0.15x————————
Return on equity—21.3%†————————
Return on assets—12.5%†————————
Return on capital employed17.2%†24.6%†————————
Asset turnover0.83x†1.08x†————————

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year endedOperating (₹ Cr)Investing (₹ Cr)Financing (₹ Cr)Capex (₹ Cr)Free Cash Flow (₹ Cr)
March 31, 2026 0 -10 10 9 -9
March 31, 2025 12 -20 9 30 -18

Balance Sheet (standalone)

Year endedTotal Assets (₹ Cr)Total Equity (₹ Cr)Reserves (₹ Cr)Borrowings, Current (₹ Cr)Borrowings, Non-current (₹ Cr)Current Assets (₹ Cr)Current Liabilities (₹ Cr)Cash & Equivalents (₹ Cr)Net Block (₹ Cr)Inventory (₹ Cr)
March 31, 2026 78 48 36 2 7 48 22 1 22 10
March 31, 2025 65 38 26 0 5 38 20 1 21 10

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.